NCT05239624 2026-04-13
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05923190 2026-03-19
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT07221942 2026-02-19
IMPROEV
Fox Chase Cancer Center
Phase 2 Recruiting
NCT05868265 2026-02-17
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06724159 2026-02-17
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
Recruiting
NCT07183319 2026-02-02
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
Phase 2 Recruiting
NCT04878029 2026-01-23
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Emory University
Phase 1 Recruiting
NCT06356155 2025-07-29
NEPTUNE
University of Michigan Rogel Cancer Center
Phase 2 Recruiting